PL3325662T3 - Wyciszenie epigenetyczne nmt2 - Google Patents
Wyciszenie epigenetyczne nmt2Info
- Publication number
- PL3325662T3 PL3325662T3 PL16826961.1T PL16826961T PL3325662T3 PL 3325662 T3 PL3325662 T3 PL 3325662T3 PL 16826961 T PL16826961 T PL 16826961T PL 3325662 T3 PL3325662 T3 PL 3325662T3
- Authority
- PL
- Poland
- Prior art keywords
- nmt2
- epigenetic silencing
- epigenetic
- silencing
- Prior art date
Links
- 101100481125 Schizosaccharomyces pombe (strain 972 / ATCC 24843) thi2 gene Proteins 0.000 title 1
- 230000001973 epigenetic effect Effects 0.000 title 1
- 230000030279 gene silencing Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194109P | 2015-07-17 | 2015-07-17 | |
| PCT/CA2016/050846 WO2017011907A1 (en) | 2015-07-17 | 2016-07-18 | Epigenetic silencing of nmt2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3325662T3 true PL3325662T3 (pl) | 2024-02-26 |
Family
ID=57833648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16826961.1T PL3325662T3 (pl) | 2015-07-17 | 2016-07-18 | Wyciszenie epigenetyczne nmt2 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11788145B2 (pl) |
| EP (1) | EP3325662B1 (pl) |
| JP (2) | JP2018521654A (pl) |
| DK (1) | DK3325662T3 (pl) |
| ES (1) | ES2964607T3 (pl) |
| PL (1) | PL3325662T3 (pl) |
| WO (1) | WO2017011907A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013013302A1 (en) | 2011-07-22 | 2013-01-31 | Pacylex Pharmaceuticals Inc. | Synthetic lethality and the treatment of cancer |
| MX2018013413A (es) | 2016-05-26 | 2019-06-06 | Zeno Royalties & Milestones Llc | Compuestos inhibidores de egfr. |
| CN106868146B (zh) * | 2017-03-06 | 2020-01-24 | 新乡医学院 | 用于检测与结直肠癌长春新碱耐药相关的miRNA表达的引物、试剂盒、方法及应用 |
| JP2020525758A (ja) * | 2017-06-04 | 2020-08-27 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズＲａｐｐａｐｏｒｔ Ｆａｍｉｌｙ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｒｅｓｅａｒｃｈ ｉｎ ｔｈｅ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅｓ | 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット |
| WO2019204758A1 (en) * | 2018-04-20 | 2019-10-24 | Zhiguo Zhang | Compositions and methods for treating glioblastoma by modulating a mgmt enhancer |
| GB201820660D0 (en) | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Cancer treatments |
| GB201820659D0 (en) | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Novel compostions and their use in therapy |
| CA3163139A1 (en) * | 2018-12-27 | 2020-07-02 | Vivienne I. Rebel | Compositions and methods for treating cancer |
| US20230255978A1 (en) * | 2020-05-12 | 2023-08-17 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| GB202014736D0 (en) | 2020-09-18 | 2020-11-04 | Imperial College Innovations Ltd | Novel compounds and their use in therapy |
| GB202017367D0 (en) | 2020-11-02 | 2020-12-16 | Imperial College Innovations Ltd | Novel use |
| CN112516141A (zh) * | 2020-12-07 | 2021-03-19 | 浙江大学 | Cd47表达抑制剂及其与免疫治疗药物联合使用 |
| AU2022327751A1 (en) | 2021-08-11 | 2024-03-21 | OncoHost Ltd. | Predicting patient response |
| WO2023164776A1 (en) * | 2022-03-03 | 2023-09-07 | Pacylex Pharmaceuticals Inc. | Oral pclx-001 in the treatment of human cancer |
| WO2024052684A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Antibody drug conjugate comprising nmt inhibitor and its use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2657259A1 (fr) | 1990-01-25 | 1991-07-26 | Adir | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
| US20030180292A1 (en) | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| KR101146806B1 (ko) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| ES2339663T3 (es) | 2003-07-25 | 2010-05-24 | Cancer Research Technology Limited | Inhibidores de parp triciclicos. |
| CN1905864B (zh) | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| ATE521341T1 (de) | 2003-12-01 | 2011-09-15 | Kudos Pharm Ltd | Dna-schäden-reparatur-hemmer zur behandlung von krebs |
| US20050255118A1 (en) | 2004-02-06 | 2005-11-17 | Nancy Wehner | Methods and composition for treating tumors and metastatic disease |
| EP1771474B1 (en) | 2004-07-20 | 2010-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| US20060141504A1 (en) | 2004-11-23 | 2006-06-29 | Willman Cheryl L | Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults |
| ES2394925T3 (es) | 2005-09-27 | 2013-02-06 | University Of Saskatchewan | Uso de N-miristoiltransferasa en tejido no tumoral para el diagnóstico de cáncer |
| CN101631466B (zh) | 2006-12-18 | 2013-02-13 | 杰克·阿比瑟 | 新钯络合物体外抑制n-肉豆蔻酰基转移酶活性和体内抑制癌生长 |
| GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| WO2013013302A1 (en) * | 2011-07-22 | 2013-01-31 | Pacylex Pharmaceuticals Inc. | Synthetic lethality and the treatment of cancer |
| ES2856701T3 (es) | 2012-10-30 | 2021-09-28 | Pacylex Pharmaceuticals Inc | Letalidad sintética y tratamiento del cáncer |
-
2016
- 2016-07-18 EP EP16826961.1A patent/EP3325662B1/en active Active
- 2016-07-18 DK DK16826961.1T patent/DK3325662T3/da active
- 2016-07-18 US US15/745,578 patent/US11788145B2/en active Active
- 2016-07-18 PL PL16826961.1T patent/PL3325662T3/pl unknown
- 2016-07-18 JP JP2018502095A patent/JP2018521654A/ja active Pending
- 2016-07-18 WO PCT/CA2016/050846 patent/WO2017011907A1/en active Application Filing
- 2016-07-18 ES ES16826961T patent/ES2964607T3/es active Active
-
2021
- 2021-10-28 JP JP2021176651A patent/JP2022023186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3325662B1 (en) | 2023-08-30 |
| US11788145B2 (en) | 2023-10-17 |
| EP3325662A4 (en) | 2019-01-02 |
| EP3325662A1 (en) | 2018-05-30 |
| ES2964607T3 (es) | 2024-04-08 |
| JP2022023186A (ja) | 2022-02-07 |
| JP2018521654A (ja) | 2018-08-09 |
| DK3325662T3 (da) | 2023-11-27 |
| US20180208990A1 (en) | 2018-07-26 |
| WO2017011907A1 (en) | 2017-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3325662T3 (pl) | Wyciszenie epigenetyczne nmt2 | |
| HK1232086A1 (zh) | 行李件 | |
| HUE057846T2 (hu) | Permanens epigenetikus géncsendesítés | |
| HK1231400A1 (zh) | 蛋白質的選擇性還原 | |
| HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
| HUE050747T2 (hu) | Poggyász | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| HUE044083T2 (hu) | Alvivõk újracstornázása | |
| HUE049290T2 (hu) | Leválasztó | |
| HK1232087A1 (zh) | 行李件 | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| SG11201707154SA (en) | Selective amplification of overlapping amplicons | |
| HK1251023A1 (zh) | 檢測一個或多個病原體 | |
| HK1245033A1 (zh) | 行李箱 | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| HK1254881A1 (zh) | 可定製儀器 | |
| HK1249866A1 (zh) | 用他塞利昔布進行治療的方法 | |
| HK1257123A1 (zh) | 新型mirna生物標誌物及其用途 | |
| HK1244667A1 (zh) | 預防二次感染的方法 | |
| IL256316A (en) | muffler | |
| IL253773A0 (en) | Treatment of dystrophy of the facial, back and arm muscles | |
| ES1137506Y (es) | Helice reductora de perdidas | |
| GB201918494D0 (en) | Detection of epigenetic modifications | |
| HUE061458T2 (hu) | Izoidid elõállítása és tisztítása | |
| GB201600964D0 (en) | Determination of vehicle capabilities |